Euronext Paris and Portzamparc (BNP Paribas Group) have informed the AMF that, at the close of the simplified tender offer (OPAS), Novo Nordisk holds 97.84% of the capital and at least 97.47% of the voting rights in the medical devices company Biocorp.

During the OPAS period, from September 7 to 27 inclusive, Novo Nordisk acquired 665,985 shares under the semi-centralized procedure and 343,223 shares through its designated buyer market member, at a unit price of 35 euros.

In all, the Danish pharmaceutical company holds 4,317,044 Biocorp shares, representing the same number of voting rights. The listing of Biocorp shares will remain suspended until the squeeze-out is implemented.

Copyright (c) 2023 CercleFinance.com. All rights reserved.